PDCD1 and neoplasm: The reinvigorated anti-tumor immunity resulting from the coincident blockade of the programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) has triggered much interest in combination therapies (Sharpe and Pauken, 2018).